Citations (28)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Javier Martínez González, Mayte Monreal, Ignacio Ayani Almagia, Jordi Llaudó Garín, Lourdes Ochoa Díaz de Monasterioguren & Ibón Gutierro Adúriz. (2018) Bioequivalence of a biosimilar enoxaparin sodium to Clexane® after single 100 mg subcutaneous dose: results of a randomized, double-blind, crossover study in healthy volunteers. Drug Design, Development and Therapy 12, pages 575-582.
Read now
Read now
Articles from other publishers (27)
Katrin Zöller, Flavia Laffleur, Victor Claus, Patrick Knoll, Dennis To & Andreas Bernkop-Schnürch. (2023) Development and in vivo evaluation of nanoemulsions for oral delivery of low molecular weight heparin. Journal of Drug Delivery Science and Technology 86, pages 104686.
Crossref
Crossref
Katherine Kramme, Paya Sarraf, Saad Shebrain & Gitonga Munene. (2021) Safety and Efficacy of Prophylactic Enoxaparin Adjusted by Anti-Factor Xa Peak Levels in Pancreatic Surgery. The American Surgeon 89:2, pages 300-308.
Crossref
Crossref
Mehdi Shafiei, Masih Sabouri, Bahram Aminmansour, Majid Rezvani, Mehdi Mahmoodkhani, Peiman Rahmani, Babak Karami, Arman Sourani & Mina Foroughi. (2022) Comparison between rivaroxaban versus enoxaparin for venous thromboembolism prophylaxis following spine surgeries, a randomized clinical trial. Journal of Clinical Neuroscience 105, pages 51-57.
Crossref
Crossref
Meng Zhang, Xiang Zhang, Chunlan Wang, Yangfang Shen & Jianan Fu. (2022) The Role of Jinhuang Powder to Prevent Adverse Effects of Subcutaneous Injection of Enoxaparin Sodium. Emergency Medicine International 2022, pages 1-6.
Crossref
Crossref
Sumit Saxena, Manu Chaudhary, Saransh Chaudhary & Anmol Aggarwal. (2022)
Bioequivalence of a biosimilar enoxaparin (
Cloti‐Xa™
) and its innovator (Clexane
®
): A
single‐dose
, randomized,
double‐blind
,
two‐period
,
two‐treatment
,
two‐sequence
, crossover, balanced study in healthy human subjects
. Pharmacology Research & Perspectives 10:4.
Crossref
Crossref
Lei Chen, Wen Zhu, Na Yan, Yan Guo, Lin Yi, Yilan Ouyang & Zhenqing Zhang. (2022) Analysis of heparinase derived LMWH products using a MHC 2D LC system linked to Q-TOF MS. Journal of Pharmaceutical and Biomedical Analysis 212, pages 114616.
Crossref
Crossref
Patrick Lu, Karl-Anton Harms, Eldho Paul, Hadley Bortz, Cheng Lo & Heather Cleland. (2021) Venous thromboembolism in burns patients: Are we underestimating the risk and underdosing our prophylaxis?. Journal of Plastic, Reconstructive & Aesthetic Surgery 74:8, pages 1814-1823.
Crossref
Crossref
Bo-Xia Li, Shi-Dong Liu, Liang Qi, Shusen Sun, Wei Sun, Yuan-Min Li, Bing Song & Xin-An Wu. (2020) Comparison of different bridging anticoagulation therapies used after mechanical heart valve replacement in Chinese patients - a prospective cohort study. Journal of Cardiothoracic Surgery 15:1.
Crossref
Crossref
Lauren E. Corona, Udit Singhal, Khaled Hafez, Lindsey A. Herrel, Samuel D. Kaffenberger, Jeffrey S. Montgomery, Todd M. Morgan, Alon Z. Weizer, Yongmei Qin & Sapan N. Ambani. (2020) Rethinking the one-size-fits-most approach to venous thromboembolism prophylaxis after radical cystectomy. Urologic Oncology: Seminars and Original Investigations 38:10, pages 797.e1-797.e6.
Crossref
Crossref
Katherine Kramme, Paya Sarraf & Gitonga Munene. (2020) Prophylactic Enoxaparin Adjusted by Anti-Factor Xa Peak Levels Compared with Recommended Thromboprophylaxis and Rates of Clinically Evident Venous Thromboembolism in Surgical Oncology Patients. Journal of the American College of Surgeons 230:3, pages 314-321.
Crossref
Crossref
Jacob E. Choby, Andrew J. Monteith, Lauren E. Himmel, Paris Margaritis, Jana K. Shirey-Rice, Andrea Pruijssers, Rebecca N. Jerome, Jill Pulley & Eric P. Skaar. (2019)
A Phenome-Wide Association Study Uncovers a Pathological Role of Coagulation Factor X during
Acinetobacter baumannii
Infection
. Infection and Immunity 87:5.
Crossref
Crossref
Audis BetheaElliot AdamsFrank C. Lucente, Damayanti SamantaJulton Tomanguillo Chumbe. (2018) Improving Pharmacologic Prevention of VTE in Trauma: IMPACT-IT QI Project. The American Surgeon 84:6, pages 1097-1104.
Crossref
Crossref
Joel M. Baumgartner, Shonté McKenzie, Shanna Block, Todd W. Costantini & Andrew M. Lowy. (2018) Prophylactic enoxaparin doses may be inadequate in patients undergoing abdominal cancer surgery. Journal of Surgical Research 221, pages 183-189.
Crossref
Crossref
Shifaza Mohamed & Deirdre Coombe. (2017) Heparin Mimetics: Their Therapeutic Potential. Pharmaceuticals 10:4, pages 78.
Crossref
Crossref
Tammy R. Kopelman, Jarvis W. Walters, James N. Bogert, Usmaan Basharat, Paola G. Pieri, Karole M. Davis, Asia N. Quan, Sydney J Vail & Melissa A. Pressman. (2017) Goal directed enoxaparin dosing provides superior chemoprophylaxis against deep vein thrombosis. Injury 48:5, pages 1088-1092.
Crossref
Crossref
S K Zyryanov & E A Ushkalova. (2016) Enoxaparin is a low-molecular-weight heparin with a complex chemical structure and various non-anticoagulant properties. Terapevticheskii arkhiv 88:12, pages 109-115.
Crossref
Crossref
George A. Singer, Gina Riggi, Charles A. Karcutskie, Tanaz M. Vaghaiwalla, Howard M. Lieberman, Enrique Ginzburg, Nicholas Namias & Edward B. Lineen. (2016) Anti-Xa–guided enoxaparin thromboprophylaxis reduces rate of deep venous thromboembolism in high-risk trauma patients. Journal of Trauma and Acute Care Surgery 81:6, pages 1101-1108.
Crossref
Crossref
Allison E. Berndtson, Todd W. Costantini, James Lane, Kevin Box & Raul Coimbra. (2016) If some is good, more is better. Journal of Trauma and Acute Care Surgery 81:6, pages 1095-1100.
Crossref
Crossref
Turgut Cavusoglu, Kemal Kismet, Namik Ozcan, Berkay Kucuk, Aziz Mutlu Barlas, Bahadir Osman Bozkirli, Pinar Celepli, Mehmet Senes, Serkan Bolat & Sema Hucumenoglu. (2016) The effects of enoxaparin on the liver in experimental pneumoperitoneum model. Acta Cirurgica Brasileira 31:11, pages 736-743.
Crossref
Crossref
Ruben Vardanyan & Victor Hruby. 2016. Synthesis of Best-Seller Drugs. Synthesis of Best-Seller Drugs
383
412
.
Matthew D Jose, Henrietta Longmuir, Benjamin Dodds, Luke Bereznicki, Ritam Prasad, Tracey J Batt, Giovanni FM Strippoli & Suetonia C Palmer. (2015) Anticoagulation for people receiving long-term haemodialysis. Cochrane Database of Systematic Reviews.
Crossref
Crossref
Cynthia M. Panek, Reid K. Nakamura & Domenico Bianco. (2015) Use of enoxaparin in dogs with primary immune-mediated hemolytic anemia: 21 cases. Journal of Veterinary Emergency and Critical Care 25:2, pages 273-277.
Crossref
Crossref
Michel Kindo, Sébastien Gerelli, Tam Hoang Minh, Min Zhang, Nicolas Meyer, Tarek Announe, Jonathan Bentz, Ziad Mansour, Arnaud Mommerot, Hélène Petit-Eisenmann, Hélène Kremer, Olivier Collange, Julien Pottecher, Mircea Cristinar, Jean-Claude Thiranos, Philippe Billaud & Jean-Philippe Mazzucotelli. (2014) Exclusive Low-Molecular-Weight Heparin as Bridging Anticoagulant After Mechanical Valve Replacement. The Annals of Thoracic Surgery 97:3, pages 789-795.
Crossref
Crossref
Geon-Hyeong Kim, Beom-Yong Park, Tae-Yong Bae, Jin-Woo Kang & Yong In. (2013) Can Enoxaparin Reduce Thromboembolism Related Events After Primary TKA In Asian Patients?. The Journal of Arthroplasty 28:10, pages 1862-1867.
Crossref
Crossref
Todd W. Costantini, Emily Min, Kevin Box, Vy Tran, Robert D. Winfield, Dale Fortlage, Jay Doucet, Vishal Bansal & Raul Coimbra. (2013) Dose adjusting enoxaparin is necessary to achieve adequate venous thromboembolism prophylaxis in trauma patients. Journal of Trauma and Acute Care Surgery 74:1, pages 128-135.
Crossref
Crossref
Randall N. Willard, Antonio E. Muñiz & Francis Chuidian. (2012) Delayed subdural hematoma after receiving enoxaparin for prevention of thromboembolic events from high-risk surgery. The American Journal of Emergency Medicine 30:6, pages 1017.e5-1017.e8.
Crossref
Crossref
Lei Chen, Wen Zhu, Na Yang, Yan Guo, Lin Yi, Yilan Ouyang & Zhenqing Zhang. (2021) Analysis of Heparinase Derived LMWH Products Using a MHC 2D LC System Linked to Q-TOF MS. SSRN Electronic Journal.
Crossref
Crossref